论文部分内容阅读
８名健康男性志愿者，随机交叉口服单剂量（３００ｍｇ）罗红霉素片剂与胶囊剂．用微生物检定法测定血药浓度．两种制剂的药－时曲线均符合二室模型．达峰时间Ｔｐｅａｋ分别为（１．５４±０．４１）与（１．９４±０．４４）ｈ；达峰浓度Ｃｍａｘ分别为（６．５０±０．３０）与（６．５０±０．２６）ｕ／ｍＬ；曲线下面积ＡＵＣ分别为（１２１．１４±１５．９１）与（１１４．６２±１４．０７）（ｕ／ｍＬ）·ｈ．两种制剂的药代动力学参数均无显著性差异（Ｐ＞０．０５）．罗红霉素片的相对生物利用度为：（１０５．８１±７．０６）％．两种制剂生物等效
Eight healthy male volunteers were randomized to receive a single dose (300 mg) of roxithromycin tablets and capsules. Microbiological determination of plasma concentration. The drug-time curves of the two formulations all fit the two-compartment model. The peak time of Tpeak was (1.54 ± 0.41) and (1.94 ± 0.44) h, respectively. The peak concentrations of Cmax were (6.50 ± 0.30) and (6.50 ± 0.30) 26) u / mL; the area under the curve AUC were (121.14 ± 15.91) and (114.62 ± 14.07) (u / mL) · h, respectively. Pharmacokinetic parameters of the two preparations showed no significant difference (P> 0.05). The relative bioavailability of roxithromycin tablets was (105.81 ± 7.06)%. Both formulations are bioequivalent